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circulating Endothelial Progenitor cells is a 
predictor in Atherosclerosis:
Is it really a promising candle?
Anwar Santoso
Circulating endothelial progenitor cells (CEPC) are 
supposed to be a subset of bone marrow­derived pe­
ripheral blood mononuclear cells (PBMC), revealing 
immature surface markers common to hematopoietic 
stem cells, such as CD 34 and CD 133 and endothe­
lial lineage markers. These cells can be isolated from 
peripheral, umbilical cord, and bone marrow blood. 
CD 34 represents a marker of immature stem cells 
that is commonly used to characterize CEPC together 
with other surface antigens. Though, as CD 34 is 
also expressed at lower levels on mature endothelial 
cells, most recent studies used CD 133, a marker of 
more immature hematopoietic stem cells that is now 
considered the best surface marker to define, identify 
and isolate the CEPC1. CD 133 (also known as AC 
133 or prominin) is highly conserved antigen with un­
known biological activity. It would be expressed on he­
matopoietic stem cells, but not on mature endothelial 
cell and monocytes. In order to reflect the endothelial 
cells, there is general agreement for the use of at least 
one additional marker, such as vascular endothelial 
growth factor receptor-2 (VEGFR­2 or KDR), while 
others are platelet-endothelial cells adhesion molecules-1 
(PECAM­1), von Willebrand factor, c­kit, Tie­2, vas-
cular endothelial-cadherin and VEGFR­12. 
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The pivotal role shown by the endothelial cells 
in cardiovascular (CV) biology has been becoming 
increasingly appreciated. Endothelial injury has been 
involved in atherosclerosis,thrombosis, and hyperten­
sion, and the balance between endothelial injury and 
endothelial recovery is of supreme importance for 
reducing CV events. Further, other studies are also 
providing intriguing and encouraging insight into the 
potential use of CEPC in the clinical setting.Indeed, 
there is accumulating evidence for reduced availabil­
ityand impaired CEPC function in the presence of 
both CV disease and associated comorbid risk factors3 
with endothelial dysfunction.
Endothelial dysfunction, detected as the presence 
of reduced vasodilating response to endothelial stimuli, 
has been observed to be associated with major CV risk 
factors, such as aging, diabetes, hypercholesterolemia, 
hypertension, smoking, hyperhomocysteinemia, and 
postmenopause state4, 5. Accordingly, endothelial func­
tion is proved to be associated with the number of CV 
risk factors and therefore with the global CV risk. This 
was also confirmed in the Framingham population, 
in which an escalating inverse relationship between 
endothelial­dependent relaxation, estimated by flow-
mediated dilatation (FMD) and the CV risk score.
Multiple studies have consistently reported an 
association between lipid metabolism and the biol­
ogy ofhuman EPC. The numbers of EPC colony 
forming unitsare significantly reduced in relatively 
healthy subjects with hypercholesterolemia5. In CAD, 
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low­densitylipoprotein (LDL) cholesterol inversely 
correlates with the number of CEPC. In addition, 
the functional characteristics of isolated EPC, such as 
proliferation, migration, adhesion, and in vitro vas­
culogenic capacity, are also impaired in patients with 
hypercholesterolemia5.
Among several CV risk factors, hypertension is the 
strongest predictor of CEPC migratory impairment. 
Angiotensin II reduces telomerase activity in CEPC 
and accelerates the onset of CEPC senescence via an 
enhanced oxidative stress6. Although angiotensin II 
inhibited CEPC proliferation in one study, but it in­
crease VEGF­induced EPC proliferation in another. 
Angiotensin II also potentiates VEGF­induced net­
work formation by CEPC, maybe by upregulation of 
KDR. Angiotensin II likely would induce increased 
shear stress, and subsequently it increases differentia­
tion, adhesion, migration, proliferation, antiapoptosis, 
and vasculogenesis of CEPC by activation of VEGFR­2 
and signal transduction pathway7.
Diabetes mellitus, another important CV risk 
factor, is a disease in which impairment of ischemia­
induced neovascularization has been described. The 
number of CEPC is reduced in diabetes1. Further­
more, marked CEPC dysfunction may underlie new 
mechanisms involved in the pathogenesis of vascular 
complications in diabetic patients1. Diminished CEPC 
supplied by diabetes may be ascribed to impaired 
CEPC production in bone marrow and to decreased 
CEPC mobilization from spleen, which may contrib­
ute to endothelial dysfunction in diabetes8. Further 
evidence of the adverse impact of hyperglycemiaon 
CEPC was shown by Kränkel et al.9, who demonstra­
ted that cultivation of PBMNC from healthy donors 
under hyperglycemic conditionswas associated with 
significant reduction in CEPC numbers, inhibition 
of NO production, and matrixmetalloproteinase­9 
activity, as well as an impairment of them igrational 
and integrative capacities of the cells.
In order to prove the reality in our own popula­
tion in Indonesia, one of the investigators recently had 
conducted the study and published in this journal. 
They recruited 55 subjects (normal subjects, those with 
CVD risk and CVD subjects) and divided them into 6 
groups, based on “Framingham risk score’. CEPC was 
measured by flow cytometry, and confirmed using CD 
34 Per CP Santa Cruz SC­19621 and CD 133 FITC 
(fluorescein isothiocyanate) Bioss bs­0395R­FITC. Fur­
ther, to indicate circulating endothelial cells (CEC), 
they were measured using CD45 FITC Biolegend 
202205 and CD 146 PE Biolegend 134704 marker. 
Unpredictably, the study suggested that: ‘increased 
EPC was associated with increased CVD risk based 
on the Framingham risk score’. This finding unfortu­
nately did not confirm the previous available studies. 
This might be explained by such following: “CEPC 
count in vitro does not provide information on the 
absolute number of CEPC10, because they depend not 
only on the initial number of progenitors, but also on 
adhesion, proliferation and survival of plated EPC, 
resulting from complex in vivo cellular interactions. 
These considerations suggest that it may be difficult to 
define the “true” population of CEPC and reflects in 
vivo setting2. Anyway, we appreciated with this initia­
tive to conduct the study, as the proverb says: ‘better 
to light a candle than to curse the darkness’. 
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